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Most drugs are not tested for use during pregnancy, consequently, labeling, which may include information about fetal safety,
includes nothing about dosing, eﬃcacy, or maternal safety. Yet these are concerns of health care providers considering treatment
of disease during pregnancy. Therefore, the practitioner treats the pregnant woman with the same dose recommended for use
in adults (typically men) or may decide not to treat the disease at all. However, is the choice of not treating a woman during
pregnancy better than dealing with the challenges which accompany treatment? This paper, which summarizes metabolic and
physiologic changes induced by pregnancy, illustrates that standard adult dosing is likely to be incorrect during pregnancy.
1.Introduction
Clinically, eﬀorts have focused on minimizing the consump-
tion of drugs during pregnancy to avoid possible adverse
fetal eﬀects. However, 50–80% of pregnant women use
prescriptionornonprescription(over-the-counterorherbal)
drugs during pregnancy [1, 2]. One investigation found
that 83% of pregnant women received at least one prescrip-
tion drug [3], with analgesics, tranquilizers, antihistamines,
antiemetics, hypoglycemics, antiasthmatics, antiepileptics,
antibiotics,anddiureticsmostwidelyused[3].Manyofthese
drugshavenotbeenadequatelystudiedforpharmacokinetics
(PK), pharmacodynamics (PD), eﬃcacy, or maternal safety
during pregnancy and consequently are used oﬀ-label [4, 5].
The optimal dose of a drug used during pregnancy
should maximize therapeutic eﬃcacy while minimizing the
risk of maternal, fetal, and placentaltoxicity. With pregnancy
being a dynamic state exhibiting numerous physiologic and
metabolic changes (see Table 1), assuming that PK, PD, and
eﬃcacy are the same as the adult male or nonpregnant
female should be considered erroneous [6]. For example,
cefatrizine, a cephalosporin antibiotic, is eliminated by renal
mechanisms and not metabolized. Pregnancy reduces the
antibiotic’s oral availability by 43%, serum concentration by
45%, and extends its elimination half-life by one hour [7].
Beyond changes in cardiovascular, pulmonary, gastroin-
testinal, renal, and hepatic function during pregnancy [8],
there are also changes in the expression and activity of
transport proteins and enzyme systems, such as cytochrome
P450 (CYP) enzymes leading to PK alterations which may
change the metabolic proﬁle of a drug.
The presence of the fetal-placental unit further distin-
guishes the pregnant state from a nonpregnant adult, and
oﬀers signiﬁcant complexity to determining a drug’s safety
proﬁle [9–11]. Developmental toxicity (death, structural
malformations,functionalabnormalities,growthrestriction,
or premature birth) is a concern throughout gestation
[12], and certain drugs or exposures may interfere with
the development and function of the placenta [13]. The
placenta may change the metabolic proﬁle of a drug during
pregnancy, for example, the placenta may be responsible for
new metabolites, not observed in the nonpregnant adult, as
recently observed for glyburide [14].
Furthermore, while adverse drug reactions are more
frequent and more severe in women, the mechanism of
which remains unknown [15, 16], little is known about
maternal adverse drug eﬀects during pregnancy. This has led
the FDA to launch the Medication Exposure in Pregnancy
Risk Evaluation Program which is intended to focus on the
maternal and fetal safety of medications during pregnancy
[17].2 Journal of Biomedicine and Biotechnology
Table 1: Pregnancy-induced physiologic changes during near term.
System [ref.] Parameter Non
pregnant Pregnant
Cardiovascular
[18, 19] Cardiac output (L/min) 4.0 7.0
Heart rate
(beats per min) 70 90
Stroke volume (mL) 65 85
Plasma volume (L) 2.6 3.5
Colloid osmotic pressure
(mmHg) 22.0 18.2
Total peripheral arterial
resistance (dyne s cm−5) 1530 1210
Respiratory [20] Total lung capacity (mL) 4225 4080
Residual volume (mL) 965 770
Tidal volume (mL) 485 680
Minute O2 uptake 201 265
Liver [21] Portal vein blood ﬂow
(L/min) 1.25 1.92
Hepatic artery blood
ﬂow (L/min) 0.57 1.06∗
Renal [22] Glomerular ﬁltration
rate (mL/min) 97 144
Creatinine (mg/dL) 0.7 0.5
∗Diﬀerence was not statistically signiﬁcant.
At a time when precise information on dosing, eﬃcacy,
and safety are needed, data is sparse or unavailable. In many
instances, each pregnant woman becomes an individual
experimental subject when it comes to dosing, eﬃcacy,
and safety, leaving the concerned practitioner to prescribe
medication without suﬃcient information or to withhold
medications because of the lack of fetal safety data. In
addition, for a comprehensive understanding of drug eﬀects
during pregnancy, research should expand to include the
multiple inactive ingredients (excipients) present in formu-
lations, a topic which has been ignored. In this review we
summarize the current understanding of PK and PD changes
during pregnancy. While our understanding of these changes
is improving, we also draw attention to data gaps, research
needs and issues of concern for practitioners.
2. Physiologic Changes of Pregnancy
Pregnancy is a complex state during which changes in phys-
iology of the maternal organism (see Table 1)h a v ee v o l v e d
to enhance development and growth of the placenta and
fetus [8, 23]. These changes also alter maternal disposition
of drugs and the eﬀect of a drug on the mother, placenta, and
fetus [24, 25].
2.1. Cardiovascular Changes during Pregnancy. In 1973,
Pirani et al. assessed cardiovascular changes during preg-
nancy and found that, on average, a woman’s cardiac output
increases early in pregnancy then plateaus at 16 weeks of
gestation at around 7L/min where it remains until delivery
[26, 27]. Stroke volume also increases to a maximum of
85mL at around 20 weeks of gestation and remains close
to that level until delivery. Pregnancy is also a time of
gradual increase in maternal heart rate, reaching 90 beats per
minute at rest during the third trimester [26]. Finally, the
same authors describe a gradual increase in plasma volume
reaching over 3.5L at 38 weeks of gestation.
Along with physiologic changes, pathophysiology is
altered during pregnancy. The hypertensive disorders,
recently reviewed by Lindheimer and Sibai, are an example
of diseases altered during pregnancy [28, 29]. Chronic
hypertension is distinguished from gestational hypertension
by the time of diagnosis [30, 31]. The former is deﬁned
as elevated blood pressure occurring earlier than 20 weeks
of gestation, compared to blood pressure elevations which
occur beyond 20 weeks for gestational hypertension.
Hypertension during pregnancy can signal the develop-
ment of preeclampsia [32], a pregnancy-speciﬁc condition,
which involves the development of hypertension and pro-
teinuria over the last half of pregnancy. The severe form of
the disease presents with hemoconcentration, thrombocy-
topenia, liver dysfunction, and seizures in some cases. The
clinical signiﬁcance of the diﬀerent hypertensive disorders
is evident with the choice of therapy; antihypertensive
medications are typically used in gestational and chronic
hypertension, but not in preeclampsia, where magnesium
sulfate is used acutely, and in the majority of cases the
treatment is delivery.
While appropriate dosing with antihypertensives is crit-
ical during pregnancy, few have been evaluated for PK or
PD in pregnancy [33]. Hogstedt and Rane studied the PK of
metoprolol in 5 pregnant women with postpartum followup
[34]. The study concluded that there was a substantial
increase in hepatic metabolism during pregnancy, which
resulted in increased clearance. The same authors expanded
their work on the drug, looking at its PD properties. In their
study, metoprolol had four-times and twice the eﬀect on
heart rate and systolic blood pressure, respectively, during
pregnancy as compared to the postpartum period. The
authors concluded that the altered cardiovascular response
to metoprolol during pregnancy may be due to increased
sensitivity or altered function of the beta-adrenergic system
[35].Theneteﬀectoftheseinvestigations,however,illustrate
thatbothPKandPDarenotﬁxedduringpregnancyandmay
be substantially diﬀerent. In support of these observations,
recentstudiesofthePKandPDofatenololduringpregnancy
demonstrateincreasedrenalclearance;however,theeﬀecton
PD remains to be fully characterized [36].
2.2. Pulmonary Changes during Pregnancy. Anatomic and
physiologic changes in pregnancy aﬀect pulmonary function
with a decrease in functional residual capacity and ∼30%
increase in minute ventilation (see Table 1). This change
resultsinhyperventilationin60–70%ofnormalpregnancies,
along with the sensation of dyspnea [49]. These changes are
most evident in pregnant woman with asthma.
The prevalence of asthma complicating pregnancy has
increased [50] ,a n di ti sn o we s t i m a t e dt h a ti ta ﬀects 8%
of pregnant women [51]. Gluck investigated this diseaseJournal of Biomedicine and Biotechnology 3
during pregnancy, observing that asthma improves in 1/3
of cases, worsens in 1/3, and remains unchanged in the last
1/3 [49]. Changes in estrogen and progesterone are thought
to improve the disease while elevation of the diaphragm,
increased pulmonary vascular permeability, and increased
gastroesophageal reﬂux have been associated with worsening
asthma [49].
Asthma during pregnancy has been linked to preterm
birth, low birth weight, congenital malformations, and
perinatal death [49]. Along with increased risk of adverse
outcomes in poorly controlled disease, the importance of
diagnosis and treatment are emphasized. Adherence to
treatment with inhaled corticosteroids has been reported to
be poor in many studies. Women with asthma have been
reported to decrease their use of inhaled corticosteroids
during pregnancy, compared to their use in the 20 weeks
before their last menstrual period [52]; this may be due
to concern regarding the safety of inhaled corticosteroids
during pregnancy [53]. Moreover, a substantial proportion
of asthmatic exacerbations during pregnancy have been
associated with nonadherence to treatment with inhaled
corticosteroids [54].
Reports of higher risk of preeclampsia and prematu-
rity with inhaled corticosteroids compared to nonsteroidal
asthma medication have made adherence even more diﬃcult
[55, 56]. A study on treatment of acute asthma in emergency
departments across the United States included 551 women
(51 pregnant and 500 not pregnant) [56]. Both groups had
similar duration of symptoms and peak expiratory ﬂow
rates [56]. However, there was a signiﬁcant diﬀerence in
treatment. Pregnant women were less likely to be given
systemic corticosteroids (44 versus 66%) in the emergency
department than nonpregnant women. This ﬁnding could
not be attributed to a concern about steroid exposure in
the ﬁrst trimester, because corticosteroids were used almost
equally in all trimesters: 53, 40, and 50% during the ﬁrst,
second, third trimesters, respectively [49]. Among those
patients who were admitted, pregnant women had lower
ﬁnal peak expiratory ﬂow rate in the emergency department
and had longer hospital stays (3 versus 2d). This inadequate
treatmentmaypartiallyexplaincontinuedasthmasymptoms
at 2wk follow-ups in pregnant patients (three times more
often than symptoms in nonpregnant patients; P = .002)
[49]. Only 41% of pregnant asthmatics seen in emergency
departments were being treated with inhaled corticosteroids
when they presented with severe disease [56], which is
suggestive of reluctance to treat asthma appropriately during
pregnancy.
Many aspects of pulmonary pharmacology during preg-
nancy remain unknown. One study has looked at inhalation
anesthetics and found that the minimum alveolar con-
centration of isoﬂurane was reduced by 28% in pregnant
women at 8–12 weeks’ gestation compared with that of
nonpregnant controls [57]. The pharmacokinetics of the
majority of inhaled drugs and those used to treat pulmonary
conditions during pregnancy have yet to be determined,
but this small observational study suggests that pulmonary
function changes during pregnancy inﬂuence both PK and
PD.
2.3. Liver Physiology. Hepatic blood ﬂow has been reported
to increase up to 160% during pregnancy, following the
increase in cardiac output [22]. Using Doppler ultrasonog-
raphy, Nakai et al. have reported on the increase in hepatic
perfusion during the third trimester compared to nonpreg-
nantlevel.Thestudyexaminedthehepaticarterialandportal
venous blood ﬂow in healthy pregnant women. The authors
found that hepatic arterial blood ﬂow did not increase sig-
niﬁcantly during pregnancy. They concluded that the major
determinant of the increase in the hepatic perfusion was
increased portal venous return [21, 58]. A change in hepatic
ﬂow inﬂuences the disposition of drugs which are highly
extracted by the liver. Theoretically, an increase in hepatic
ﬂow could increase hepatic extraction of drugs from portal
venous or arterial blood and result in lower bioavailability or
increased clearance, respectively. Nevertheless, data on drugs
with high extraction ratios showed variable changes in PK
properties, suggesting the presence of additional hepatic and
gastrointestinal mechanisms of drug disposition which are
altered during pregnancy [59].
Plasma protein binding of drugs, which generally
decreases during pregnancy, has important implications for
drug disposition and action. It is therefore possible that an
increased free fraction of the drug is responsible in part for
changes in its clearance. During pregnancy, both albumin
and alpha 1-acid glycoprotein (AAG) concentrations are
reduced, likely due to a dilutional eﬀect of increased plasma
volume, as well as increased urinary albumin excretion [59–
61].
Furthermore, maternal and fetal plasma diﬀer in their
concentrations of both albumin and AAG which can inﬂu-
ence a drug’s plasma concentration in maternal and fetal
circulations. Albumin is more concentrated in fetal plasma,
and AAG is at 37% of the maternal concentration in
term babies [62]. Such a diﬀerence in albumin and AAG
concentrations can signiﬁcantly alter the concentration and
relative distribution of drugs between maternal and fetal
plasma. For example, the unbound fraction (free fraction)
of indinavir and saquinavir have been found to be higher
in umbilical cord than maternal plasma [63]. These ﬁndings
were in part explained by the lower concentration of AAG in
fetal blood. Further decreasing fetal exposure to these drugs
isthefetaltomaternaleﬄuxofthesedrugsbyplacentalP-gp,
which further lowers the concentration of the drugs in the
fetal circulation [63, 64].
The transport proteins, responsible for inﬂux or eﬄux
of many diﬀerent substances into organs like the kidney,
placenta, gut, or liver play an important role in drug delivery
as well as drug-drug interactions, and they are discussed in
more detail below [65, 66].
2.4. Renal Physiology during Pregnancy. An early change in
pregnancy is systemic vasodilation which is thought to be
mediated by progesterone and relaxin [8, 70]. Dilation of
renal vasculature with an increase in glomerular ﬁltration
rate (GFR) and eﬀective renal plasma ﬂow (RPF) also occurs
[71]. Both RPF and GFR are increased, with RPF increasing
up to 1.8-fold, and GFR increasing up to 1.6-fold compared
with prepregnancy or postpartum values [8, 72].4 Journal of Biomedicine and Biotechnology
Table 2: Pregnancy-induced pharmacokinetic changes for selected drugs.
Drug Half-life Clearance Protein binding
(%) Bioavailability Time during pregnancy
change noted Reference
Cefatrizine Decreased (1.5h) Increases 60 43% 19–24 weeks [7]
Amoxicillin Decreased (1.2h) Increases 95% Delivery second and third
Trimester and postpartum [37, 38]
Cefuroxime Decreased (44min) Increases 30–50% Delivery [39]
Zidovudine Unchanged (1.1h) Increases <25 63% Delivery [40]
Lamivudine Unchanged (6h) No change 10–50 55% 38 to Delivery [41]
Saquinavir Unchanged (9–15h) 98% Delivery [40]
Lopinavir Unchanged (5-6h) Decreases 99% 37% 30–36 weeks [42]
Nelﬁnavir Unchanged (3–5h) 98% 2nd and 3rd trimester [43]
Ritonavir Unchanged (3–5h) 99% Delivery [40]
Glyburide Unchanged (4h) Increases 98% Decreases 28–38 weeks [44]
Digoxin Decreased (38h) Increases 33% 60% 3rd trimester [45, 46]
Midazolam Unchanged (2.5h) Increases 30% 24% 28–32 weeks [46]
Lamotrigine 15–24h Increases 98% 55% Throughout pregnancy [47]
Caﬀeine Increased (10.5h) Decreases 36–40 weeks [48]
Despite increased GFR and renal blood ﬂow among
pregnant women, diﬀerences have been noted in the clear-
ance of drugs which are predominantly eliminated by renal
mechanisms. Lithium is almost completely eliminated by
renal mechanisms. Women using lithium during the third
trimester demonstrated a doubling of clearance compared to
prepregnancy [73]. In comparison, the clearance of atenolol,
also eliminated predominantly by renal mechanisms, was
only increased by 12% across pregnancy [36]. Similarly, the
clearance of digoxin, which undergoes 80% renal excretion,
was increased by 20–30% during the third trimester when
compared to postpartum [45, 46]. Such variations in drug
clearances restrict any generalization about the eﬀect of
pregnancy on renally eliminated drugs. Speciﬁc evaluation is
needed to determine whether changes in clearance are due to
GFR, tubular secretion or reabsorption, or other physiologic
or metabolic processes. Table 2 summarizes pregnancy-
induced PK changes in the drugs listed above.
3. DrugTransporters
Previously, drug-drug interactions were thought to involve
the phase I or phase II enzymes. Over the past two decades,
a number of important human drug transporters that are
expressed at the apical or basal side of epithelial cells
in various tissues, including the placenta [66], have been
described [74, 75]. Given the role of transport proteins in
the transfer of drugs into or out of cells, the impact on drug-
drug interactions that these transport proteins can play in
achieving therapeutic goals in pregnancy remains ill-deﬁned
(Table 3).
Like the enzymes involved in phase I and phase II
metabolism of drugs, it is possible that drugs can interact
at transport proteins by induction, inhibition, agonistic,
or antagonist actions. For example, ritonavir is often used
in combination with other protease inhibitors to compete
with cellular elimination because it competes with P-gp (see
Table 3 and subsequent discussion of protease inhibitors). A
similar phenomenon occurs with coadministration of drugs
which are substrates interacting with other drug transporters
[76]. Also, numerous polymorphisms have been identiﬁed in
transportergenes[76,77].However,manychallengesremain
in the understanding of the clinical relevance of these genetic
variations in transporters for drug disposition and drug-
drug interactions across the course of pregnancy, especially
in the context of placental transport from and into the fetal
compartment [66].
In addition to genetic variation, changes to drug trans-
porters can ensue when physiologic changes occur. Just like
the cytochrome P450 enzymes’ activity or amount is altered
in pregnancy, it is postulated that such changes also involve
drug transporters but have yet to be described in detail
[78, 79]. Most of the studies on drug transporters during
pregnancy have focused on placental transporters [80–87].
Hebert et al. assessed the PK and PD of glyburide in
women with gestational diabetes. They observed that plasma
concentrations of glyburide during pregnancy were about
half that observed in nonpregnant women with type 2
diabetes. In addition, beta cell responsiveness was lower in
women with type 2 diabetes than other pregnant women.
The lower plasma concentrations of glyburide observed dur-
ing pregnancy were attributed to increased intestinal and/or
hepatic metabolism [44]. The increased levels of unbound
glyburide metabolites supported the authors’ conclusions.
The placenta performs many functions that aﬀect both
mother and fetus. It produces and secretes hormones which
aﬀect the maternal endocrine state [88]. It assists in fetal
growth and development by transporting nutrients towards
the fetal side and transporting products of fetal metabolism
for excretion by the mother [74, 75].
The placenta is a selective transporter for multiple com-
pounds [74]. The selective nature of the transport activity
is mediated by the polarized nature of syncytiotrophoblast,Journal of Biomedicine and Biotechnology 5
Table 3: Major ABC drug eﬄux transporters, their placental localization, and substrates.
Transporter Gene Placental localization
Gestational-age-
dependent
regulation
Substrate Inhibitor Inducer
P-gp ABCB1 Apical,
syncytiotrophoblast Yes
Digoxin,
fexofenadine,
indinavir, vincristine,
colchicines,
topotecan, paclitaxel,
talinolol, loperamide
Ritonavir, cyclosporine,
verapamil, erythromycin,
ketoconazole,
itraconazole, quinidine,
elacridar, azithromycin,
valspodar
Rifampin, St.
John’s wort
MRP1 ABCC1
Basolateral,
syncytiotrophoblast
predominantly at fetal
blood endothelia
Yes
Adriamycin,
topotecan,
cisplatinum,
methotrexate,
etoposide, vincristine
Probenecid,
sulﬁnpyrazone,
indomethacin,
glibenclamide, agosterol
A, verapamil, cyclosporin
A, genistein, quercetin,
RU486, budesonide,
agosterol A
MRP2 ABCC2 Apical,
syncytiotrophoblast Yes
Vincristine,
etoposide,
doxorubicin,
epirubicin,
methotrexate,
irinotecan, ampicillin,
ceftriaxone,
pravastatin,
temocaprilat,
grepaﬂoxacin, BQ-12,
saquinavir, ritonavir,
indinavir,
99mTc-Sestamibi
Probenecid,
sulﬁnpyrazone,
benzbromarone, MK571
Sulﬁnpyrazone
MRP3 ABCC3
Basolateral,
syncytiotrophoblast
predominantly at fetal
blood endothelia
Unknown
Etoposide,
methotrexate,
tenoposide,
acetaminophen
Probenecid,
sulﬁnpyrazone,
benzbromarone, MK571
MRP4 ABCC4 Unknown Unknown
Azidothymidine
monophosphate,
lamivudine,
ganciclovir,
6-mercaptopurine,
6-thioguanine,
methotrexate
Probenecid,
benzbromarone,
sulﬁnpyrazone, MK571,
dipyridamole
MRP5 ABCC5
Preferentially
basolateral,
syncytiotrophoblast,
and fetal vessels
Yes
Benzbromarone,
sulﬁnpyrazone, MK571,
dipyridamole
Sildenaﬁl
MRP6 ABCC6 Unknown Unknown Conjugated organic
anions
MRP7 ABCC10 Uknown Unknown Organic anions
BCRP ABCG2 Apical
syncytiotrophoblast Yes
Daunorubicin,
doxorubicin,
topotecan,
rosuvastatin, AZT,
lamivudine
Elacridar, acridone
carboxamide,
fumitremorgin C
OCT3 SLC22A3 Basal
syncytiotrophoblast Cimetidine
Desipramine,
phenoxybenzamine,
quinine
OCTN1 SLC22A4 Apical
syncytiotrophoblast
Quinidine,
verapamil
References: [67–69].6 Journal of Biomedicine and Biotechnology
the functional cells of the placenta, with support of polarity
provided by transport proteins [66]. The plasma membrane
of these cells consists of a brush border membrane that
faces the maternal side, and a basal membrane that faces
the fetal side. On the maternal side, blood ﬂows directly
from the uterine vasculature through intervillous spaces
to the syncytiotrophoblast without an intervening capillary
network. In contrast, the fetal vessels form a capillary
network within the placental villi on the fetal side.
Compounds transported between mother and fetus,
must cross the syncytiotrophoblast, through the stroma of
the villi, across the basement membrane and endothelium
of placental capillaries before entering fetal circulation. The
placenta facilitates this process as a result of diﬀerential
expression of various transporters [89–92]. Transporters are
expressed to serve speciﬁc functions by transporting endoge-
nouscompounds(suchascytokines,nucleosideanalogs,and
steroid hormones); however, exogenous compounds with
similar structures may also interact with these transporters.
Expression of placental drug transporters is under develop-
mental control and depends on gestational age [67], with
expression increasing, for some transporters, with advancing
gestational age. Such a pattern of expression indicates that
fetal exposure changes with gestational age [93–95]. It has
also been shown that placental transporter expression is
altered by maternal disease in rodent models [78, 79].
Protease inhibitors, an important drug class used in
highly active antiretroviral therapy in HIV-infected individ-
uals, have a low and variable oral availability [96]. This
means that patients have to take the drugs more frequently
and at higher doses which can lead to poor adherence and
associated low and variable drug plasma concentrations. It
has been shown that when saquinavir is coadministered
with ritonavir, both protease inhibitors, its oral availability
increases dramatically [97]. Two mechanisms have been
proposed to explain this ﬁnding. It has been demonstrated
that inhibition of the metabolizing CYP3A4 and other
cytochrome P450 isoforms by ritonavir is a major factor in
the dramatically increased saquinavir bioavailability [98]. In
addition, ritonavir has been reported to be a P-gp inhibitor
and saquinavir a substrate [99–101]. When saquinavir
and ritonavir are coadministered, ritonavir inhibits P-gp
function, resulting in increased saquinavir bioavailability.
Another drug acted upon by P-gp is lopinavir, a protease
inhibitor that had become standard therapy for HIV during
pregnancy. Studies have shown that pregnancy results in
reduced lopinavir levels when compared to postpartum [42],
doubling of the dose is needed during pregnancy to reach
therapeutic concentrations, a phenomenon that disappears
within 2 weeks postpartum [102]. These ﬁndings stress
the need for tight dosing and close monitoring to avoid
subtherapeutic levels as well as toxicity.
Another example where drug transporters have signiﬁ-
cant clinical implications is treatment of fetal tachycardia.
While transplacental pharmacotherapy for the condition
is available, it remains a challenging task to maximize
fetal drug exposure, while minimizing drug exposure of
the mother. Despite some challenges, digoxin is commonly
used as an initial monotherapy [103]. Digoxin’s clearance
increases during pregnancy leading to lower steady-state
serum concentrations [46, 104]. These changes have been
attributed to an increase in renal clearance of the drug,
due partly to an increased glomerular ﬁltration during
pregnancy, but also to increased P-gp transport of the
drug. P-gp is responsible for the increased secretion of
digoxin across the apical membrane of the renal tubular
epithelium [105, 106]. In addition, P-gp is expressed on
the maternal surface of the placenta and acts to further
decrease fetal exposure to the drug, complicating treatment
of fetal arrhythmias. These pharmacokinetic changes require
anincreaseinthedoseorachangeinthedosingintervalused
during pregnancy to maintain therapeutic concentrations
[104]. The need for increased digoxin during pregnancy
carries an underlying risk for increased maternal digoxin
toxicity. Despite the lengthy history of the drug, its toxicity
is severe and well deﬁned, with a 41% rate of mortality
and a 47% rate of life-threatening arrhythmia in individuals
who suﬀer from it. The risk for women is intensiﬁed by
data suggesting that women are at increased risk for digoxin
toxicity when compared to men across all age groups [11].
With the accumulating evidence on drug transporters,
there is little doubt that their expression and regulation play
a critical role in modulating the exposure of the mother,
placenta, and fetus to potentially harmful drugs, endogenous
toxic compounds, and potentially beneﬁcial drugs such as
retrovirals.Currentlythereisaneedtodevelopnewstrategies
for PK studies in pregnancy which recognizes the critical
role of transport proteins. In addition, further development
of models for understanding the regulation of placental
transporters by inhibitors and inducer compounds could
prove valuable in improving fetal drug availability and
decreasing toxicity.
4. DrugMetabolism
4.1.PhaseIMetabolism. ThecytochromeP450(CYP)system
is the predominant oxidative enzyme system involved in
human drug metabolism and plays a critical role in drug
disposition [121] .An u m b e ro fr e c e n ts t u d i e sh a v ee v a l u a t e d
the changes aﬀecting drug metabolism during pregnancy
(see Table 4 for summaries of some of these studies).
4.1.1. CYP3A. CYP3A is the most abundant P450 enzyme in
the liver and gut, and results in 30% of the enzyme complex’s
activity.Ithasabroadspectrumofsubstrates,andisinvolved
in some way in the metabolism of more than half of the
currently known drugs [107, 121].
Midazolam is a selective substrate for the enzyme. One
study measured a doubling in oral midazolam clearance
during pregnancy as compared to postpartum, leading
to a decrease in drug bioavailability [46]. In addition,
other research on CYP3A substrates has suggested that its
activity is increased during pregnancy. N-demethylation of
dextromethorphan, a substrate used as a probe for the
enzyme, has been reported to increase by 35–38% during
pregnancy [121]. Similarly, nelﬁnavir was reported to have
a 25–33% increase in apparent oral clearance in pregnancy
[108, 109].Journal of Biomedicine and Biotechnology 7
Table 4: Pregnancy-induced enzyme-speciﬁc changes.
Enzyme
Pregnancy-
induced
change
Potential substrates in
obstetrics Possible clinical consequences Ref.
CYP3A4 Increased Nifedipine,
methadone, indinavir
Signiﬁcantly lower trough levels of
methadone during pregnancy associated
with symptoms of withdrawal. Increase
daily dose by 5–10mg or administer in
more frequent doses to avoid withdrawal
[107–110]
CYP2D6 Increased
Metoprolol,
dextromethorphan,
paroxetine,
duloxetine,
ﬂuoxetine, citalopram
Increased metabolism of ﬂuoxetine
desmethylcitalopram,
lower plasma levels of the drug are
associated with recurring symptoms of
depression
[107, 111]
CYP1A2 Decreased
Theophylline,
clozapine, olanzapine,
ondansetron,
cyclobenzaprine
Increase in theophylline half-life during
pregnancy requiring dose reductions to
avoid toxicity
[107, 112–114]
UGT1A4 Increased Lamotrigine
Signiﬁcant decrease in lamotrigine
concentration resulting in loss of seizure
control, recommended to measure
plasma lamotrigine concentrations
during each trimester and adjusting dose
as needed
[115–117]
UGT1A1 Increased Acetaminophen
Increased acetaminophen
glucuronidation resulting in decreased
half-life,
clinical consequences are unknown
[118]
NAT2 Decreased Caﬀeine Decreased metabolism of caﬀeine
Clinical consequences are unknown [114, 119, 120]
Because CYP3A is involved in the metabolism of many
drugs, the ﬁndings have implications for medication dosing
in pregnancy [107, 121]. Those with a narrow therapeutic
window may fall below clinically eﬀective concentrations.
Also, medication started during pregnancy might reach
toxic concentrations if continued during the postpartum
period. More information is needed about this enzyme. The
enzyme’s expression and activity during pregnancy have yet
to be fully described, and it has multiple substrates that
overlap with the P-glycoprotein transporter, which itself is
aﬀected during pregnancy.
4.1.2. CYP2D6. CYP2D6 is the second most common
enzyme in the CYP family [107]. The individual status
of CYP2D6 activity can be assessed with several drugs
such as metoprolol and dextromethorphan. Low activity
of the enzyme (the poor metabolizer (PM) phenotype) is
an autosomal recessive trait that aﬀects approximately 7%
of Caucasians and 1% of Orientals [122]. The opposite
phenotype, called ultrarapid metabolism, also exists and is
caused by gene ampliﬁcation [122]. With standard medi-
cation dosing, the poor metabolizer has very high concen-
trations of the parent drug and the ultrarapid metabolizer
very low plasma concentrations. CYP2D6 activity, assessed
with dextromethorphan O-demethylation, was found to
gradually increase throughout pregnancy as compared with
the postpartum period, interpreted by some investigators as
induction during the third compared to the ﬁrst trimester
[111, 121].
4.1.3. CYP1A2. Many studies have reported decreased
CYP1A2 activity during pregnancy [48, 107, 112, 113, 121,
123]. Caﬀeine (a substrate frequently used to measure
CYP1A2 activity) has its half-life increased from 3.4h in
nonpregnant patients to 8.3h during pregnancy, with values
returning to prepregnant levels shortly after delivery [112,
114,119].AstudybyBrazieretal.showedanormalizationof
caﬀeine clearance within four days after delivery, compared
toa65%reductionduringthethirdtrimester[114].CYP1A2
activity decreases gradually with advancing gestational age.
Tracy et al. reported a reduction in caﬀeine clearance of 33%,
48%,and65%foreachtrimestercomparedwithpostpartum
[121].
Theophylline, also metabolized by CYP1A2, has de-
creased clearance during the third trimester of pregnancy
withhalf-lifeestimatedat13hcomparedto9.5hpostpartum
[124]. This change has been attributed to a reduction in
nonrenal intrinsic clearance and calls for a decrease in
theophylline doses used in later stages of pregnancy.
A more comprehensive understanding of the regulation
of the enzyme and the changes aﬀecting its numerous
substrates is needed. With the current evidence, it may be
necessary to decrease the dose of CYP1A2 substrates when
used during late pregnancy to avoid toxicity.8 Journal of Biomedicine and Biotechnology
4.2. Phase II Metabolism
4.2.1. Uridine 5 -Diphosphate Glucuronosyltransferase
(UGT). Approximately 1.1 million women with epilepsy are
of child-bearing age in the United States and give birth to
over20,000babieseachyear[125].Pregnancyinwomenwith
epilepsy is accompanied by increased maternal risks from
seizure occurrence and potential adverse developmental
outcomes related to certain antiepileptic drugs [115, 116]
Lamotrigineisanantiepilepticdrugwhosemetabolismis
signiﬁcantly altered during pregnancy. It is a UGT substrate
(see Table 4), and approximately 90% of its metabolism is
through N-glucuronidation by UGT1A4 in the liver [118].
One study reported a 360% increase in lamotrigine clear-
ance between prepregnancy and the third trimester [118].
In addition, a study of pregnant women on lamotrigine
monotherapyreportedasigniﬁcant27%decreaseintheratio
of serum concentration-to-dose during the ﬁrst trimester
and 66% decrease in the third trimester, compared to
postpartum [47]. Five of the eleven women suﬀered seizures
while enrolled in this study and required an increased dose
in order to achieve seizure control. Lamotrigine metabolism
returned to nonpregnant levels within 3 weeks after delivery
a n dr e q u i r e dad o s er e a d j u s t m e n tt oa v o i dt o x i c i t y[ 47].
Other UGTs also undergo increased activity. The clear-
ance of acetaminophen is 58% higher during pregnancy,
secondary to a 75% increase in glucuronidation activity of
UGT1A1 and -1A6 during pregnancy [126]. Similar ﬁndings
have been reported for oxazepam. The drug, metabolized by
UGT2B7, was found to have a two- to threefold increase in
clearance in pregnant women compared to clearance rates in
men and nonpregnant women [127].
Current data suggests a possible hormonal regulation
of UGTs. When taken with oral contraceptives, both lam-
otrigine and acetaminophen demonstrate decreased maxi-
mum concentration and concentration-to-dose ratio [120],
thought to be mediated by estrogen [128]. Studies in mice
describe a possible role for prolactin in UGT induction
[129]. Such ﬁndings suggest the need for continued drug
monitoring while a woman is lactating.
4.2.2. N-Acetyltransferase. Sulfamethoxazole, commonly
used during pregnancy, is a substrate of N-acetyltransferase
(NAT). Studies involving sulfamethoxazole and other
substrates of NAT suggested a decreased activity of the
enzyme during pregnancy [129]. NAT might also be under
hormonal regulation, since women on oral contraceptives
experience decreased NAT2 activity [130]. More studies
are needed to better determine changes aﬀecting drugs
metabolized by NAT and the regulation it undergoes.
5. Ethics of Drug Studies in PregnantWomen
Current medication labeling typically only reports on fetal
safety issues with respect to the use of the medication, and
typically provides no information on PK, PD, or eﬃcacy
during pregnancy. Unfortunately, it follows that if a drug
is not studied for a condition unique to pregnancy (e.g.,
preterm labor, asthma during pregnancy), treatment during
pregnancy is not considered an indication for regulatory
purposes (i.e., use of the drug is considered oﬀ-label). Such
illustrative use of medications during pregnancy was the
focus of a Cochrane report by Webb et al. The authors noted
the absence of any objective trial-based evidence to guide the
treatment of psychosis during pregnancy [131]. Treatment
was based on personal clinical judgment, which raises
“important clinical and ethical concerns for the current use
of antipsychotic drugs for women during pregnancy” [131].
McCullough et al. approached the complex matter of
maternal and fetal patients and developed a framework for
pharmacologic studies in pregnant women. The authors
deﬁned the previable fetus as a patient only when the
pregnant woman confers this dependent moral status on it,
which she has the freedom to do [132]. The viable fetus
was deﬁned as a patient by virtue of both its ability to
survive ex utero and access to medical technology which
makes this possible [133]. In research that is designed to
beneﬁt the pregnant patient, the ethical concept of the fetus
as a patient requires the pregnant woman to consider the
health-relatedinterestsofthefetusagainstherownlegitimate
interest in participating in research which may improve her
own health [134]. Conversely, a study designed to determine
ifanintervention beneﬁtsthefetus(e.g.,fetalsurgery)would
require that the pregnant subjects take only reasonable risks
to their own health [134].
This framework allows women the right to withhold
the moral status of being a patient from a previable
fetus. This adds an additional ethical consideration to a
pregnancy that is complicated by an adverse fetal event
attributed to the pharmacologic agent being studied. Such
an adverse fetal event pertains to the legal liability of the
investigator, the funder, and the sponsoring organization.
Preventing unnecessary liability to these parties would count
as self-interest. McCullough et. al suggest that when studies
follow the beneﬁcence-based obligation, they would oﬀer a
balanced protection to the study personnel as well as the
fetal patient [132]. Their paper lists four criteria for drug
studies during pregnancy that, when satisﬁed, would not
violate any beneﬁcence-based obligations to the fetal patient.
These criteria prioritize the use of drugs that are predicted to
alter the course of a pregnant woman’s condition, as well as
having previous animal or human studies that do not report
“documented death or documented serious, far-reaching,
and irreversible injury of any major organ system to the fetal
or maternal patient.” In addition, the criteria stress the need
for data demonstrating minimized risk to the fetal patient
[132]. Though this list does not exclude drugs lacking any
previous animal or human safety and/or teratogenic studies,
itdoesdiscouragetheprioritizationofstudiesforsuchagents
[132].
Ad i ﬀerent dimension to the ethics of drug studies
during pregnancy involves study design. Less risk would
be associated with a retrospective study. However, such a
study would oﬀer limitations to standardizations of patient
characteristics and drug use. Although diﬃcult, the optimal
drug study design would be a double-blind placebo or
active agent controlled trial. Some situations limit the use
of such a design. Yonkers states “it is neither ethical norJournal of Biomedicine and Biotechnology 9
practical to randomly assign depressed pregnant women
to antidepressant agents compared with placebo” [135].
Other authors support such a position. Brody explains “the
more serious the disease process and the less likely that
the established therapy will produce bad side eﬀects, the
more problematic is a placebo-controlled trial” [136]. It is
plausible to understand how such a situation would inhibit
the use of placebo but allow for controlled randomized trials
to compare diﬀerent agents.
6. Conclusion
Pregnancy alters the disposition and eﬀect of drugs and
consequently can change eﬃcacy and appropriate use of
the medication. In the setting of prescribed drugs, simply
describing pregnant women as a special population is
a mistaken oversimpliﬁcation. In current practice, each
pregnant woman is a study population of one every time she
is treated with a medication which has not been previously
studied in pregnancy to deﬁne PK, PD, or eﬃcacy. However,
drugscontinuetobeusedduringpregnancywithincomplete
data on the maternal consequences of use in pregnancy.
In addition, pregnancy has yet to lead to consideration of
drug dose alterations, with changes occurring in a case-by-
case fashion. This review has described physiological and
metabolicchangeswhichincreaseordecreasedrugclearance,
metabolism,andeﬃcacy.Giventhepaucityofunderstanding
about pregnancy-related changes in PK, PD, and eﬃcacy, it
is necessary at the present time to speciﬁcally study drugs
intended to be used in pregnancy. As this database grows it
may be possible to simulate expected changes to anticipate
improvements in study design and clinical therapeutics.
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